Similar to the cell surface IL-6R expression patterns, the levels of sIL-6R were significantly upregulated in the bone marrow of patients with high-risk MDS, but not in low-risk subtypes (Figure 6E). This evidence concerns the gene IL6R and myelodysplastic syndrome.